Effects of Pitavastatin on Adiponectin in Patients with Hyperlipidemia

Inami, Norihito; Nomura, Saori; Shouzu, Akira; Omoto, Seitaro; Kimura, Yutaka; Takahashi, Noriyuki; Tanaka, Atsushi; Nanba, Masayuki; Shouda, Y.; Iwasaka, Toshiji

doi:10.1159/000112633

Cited by 46 publications

(39 citation statements)

References 68 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, no significant reduction of the plasma MCP-1 levels was found in the pitavastatin-treated group either. We previously reported that pitavastatin could cause an elevation of adiponectin in hyperlipidemic patients with type 2 diabetes [55,56]. In these reports, we inferred two possibilities about this mechanism, which were an inhibition of production/activity of ROS and an influence on adipocyte physiology via effects on sterol regulatory element-binding proteins-1c [57].…”

Section: Discussionmentioning

confidence: 88%

Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

Nomura

Shouzu²,

Omoto

et al. 2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

The effects of statins on platelet activation markers, chemokines and adiponectin, were investigated in 135 patients with hyperlipidemia. Of the 135 hyperlipidemic patients, 63 were allocated to the simvastatin group, treated with simvastatin at the dose of 10 mg daily, and the remaining 72 were allocated to the pitavastatin group, treated with pitavastatin at the dose of 2 mg daily. Plasma levels of platelet-derived microparticles (PDMP), cell adhesion molecules (sCD40L and sP-selectin), chemokines [monocyte chemoattractant protein-1 (MCP-1) and regulated on activation normally T-cell expressed and secreted] and adiponectin were measured at the baseline and after 6 months of treatment in both the groups. In addition, we carried out a basic study to investigate the MCP-1-dependent induction of tissue factor expression on a histiocytic cell line (U937 cells). The plasma levels of PDMP, sCD40L, sP-selectin, regulated on activation normally T-cell expressed and secreted and MCP-1 were higher, whereas those of adiponectin were lower, in the hyperlipidemic patients than in the normolipidemic controls. Plasma PDMP and sCD40L were positively correlated, whereas plasma adiponectin was negatively correlated, with the plasma levels of MCP-1. No significant differences in the plasma levels of PDMP, sCD40L, sP-selectin, regulated on activation normally T-cell expressed and secreted and MCP-1 measured before and after treatment were observed in either the simvastatin or pitavastatin group. A significant increase of the plasma adiponectin levels was observed after 6 months of treatment with pitavastatin but not after an equal duration of treatment with simvastatin. When pitavastatin-treated patients were divided into two groups according to the adiponectin response to pitavastatin treatment, significant decreases of the plasma MCP-1, PDMP and sCD40L levels were observed after pitavastatin treatment in the responder group. In the aforementioned basic study, MCP-1 by itself did not induce the expression of tissue factor on the U937 cells. However, the recombinant sCD40L-induced expression of tissue factor on U937 was enhanced by the addition of MCP-1. These findings suggest that PDMP, sCD40L and MCP-1 may participate in the development of atherothrombosis in patients with hyperlipidemia and that pitavastatin may exert an adiponectin-dependent antiatherothrombotic effect in hyperlipidemic patients.

show abstract

Section: Discussionmentioning

confidence: 88%

Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

Nomura

Shouzu²,

Omoto

et al. 2009

Blood Coagulation &Amp; Fibrinolysis

View full text Add to dashboard Cite

show abstract

“…Recently, it was reported that adiponectin influences the value of HDL-C 21) . Pitavastatin increases adiponection in hyperlipidemic patients 22) . Since the concentration of adiponectin is lower in diabetes patients than non-diabetes patients 23) , adiponectin could mediate HDL-C elevation in diabeteic patients by pitavastatin.…”

Section: Discussionmentioning

confidence: 99%

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

Teramoto

Shimano

Yokote

et al. 2009

JAT

View full text Add to dashboard Cite

show abstract

“…80 Several clinical studies have also found that pitavastatin possesses an adiponectin-increasing effect in hyperlipidemic patients with and without T2D. [85][86][87][88][89][90] Adiponectin is a protein with antiatherosclerotic, anti-inflammatory, and antidiabetogenic properties exerted on liver, skeletal muscle, adipose tissue and pancreatic β-cells. 90 Mechanistically, adiponectin stimulates AMPK, a kinase that suppresses energy-consuming pathways such as hexosamine and cholesterol biosynthesis.…”

Section: Review Diabetesmentioning

confidence: 99%

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Grice

Elmendorf

2017

US Endocrinology

View full text Add to dashboard Cite

Cholesterol is an essential component of cell membranes, and during the past several years, diabetes researchers have found that membrane cholesterol levels in adipocytes, skeletal muscle fibers and pancreatic beta cells influence insulin action and insulin secretion. Consequently, it is thought that dysregulated cell cholesterol homeostasis could represent a determinant of type 2 diabetes (T2D). Recent clinical findings compellingly add to this notion by finding increased T2D susceptibility in individuals with alterations in a variety of cholesterol metabolism genes. While it remains imperfectly understood how statins influence glucose metabolism, the fact that they display an influence on blood glucose levels and diabetes susceptibility seems to intensify the emerging importance of understanding cellular cholesterol in glucose metabolism. Taking this into account, this review first presents cell system and animal model findings that demonstrate the negative impact of cellular cholesterol accumulation or diminution on insulin action and insulin secretion. With this framework, a description of how changes in cholesterol metabolism genes are associated with T2D susceptibility will be presented. In addition, the connection between statins and T2D risk will be reviewed with expanded information on pitavastatin, a newer statin medication that displays actions favoring metabolic health.

show abstract

Effects of Pitavastatin on Adiponectin in Patients with Hyperlipidemia

Cited by 46 publications

References 68 publications

Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

Effects of pitavastatin on monocyte chemoattractant protein-1 in hyperlipidemic patients

Effects of Pitavastatin (LIVALO Tablet) on High Density Lipoprotein Cholesterol (HDL-C) in Hypercholesterolemia Sub-Analysis of LIVALO Effectiveness and Safety (LIVES) Study

New Aspects of Cellular Cholesterol Regulation on Blood Glucose Control—Review and Perspective on the Impact of Statin Medications on Metabolic Health

Contact Info

Product

Resources

About